Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 1
2012 2
2013 2
2014 1
2015 3
2016 4
2017 4
2018 5
2019 7
2020 6
2021 5
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials.
Vantourout P, Eum J, Conde Poole M, Hayday TS, Laing AG, Hussain K, Nuamah R, Kannambath S, Moisan J, Stoop A, Battaglia S, Servattalab R, Hsu J, Bayliffe A, Katragadda M, Hayday AC. Vantourout P, et al. Among authors: battaglia s. Sci Adv. 2023 Dec 8;9(49):eadj6174. doi: 10.1126/sciadv.adj6174. Epub 2023 Dec 6. Sci Adv. 2023. PMID: 38055824 Free PMC article.
Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8+ T‑cells from GzmB mediated self‑destruction.
Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Zangari B, et al. Among authors: battaglia s. Cancer Immunol Immunother. 2022 Dec;71(12):2899. doi: 10.1007/s00262-022-03233-1. Cancer Immunol Immunother. 2022. PMID: 35666273 Free PMC article. No abstract available.
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.
Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Zangari B, et al. Among authors: battaglia s. Cancer Immunol Immunother. 2022 Dec;71(12):2881-2898. doi: 10.1007/s00262-022-03197-2. Epub 2022 Apr 23. Cancer Immunol Immunother. 2022. PMID: 35460379 Free PMC article.
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Odunsi K, et al. Among authors: battaglia s. Sci Transl Med. 2022 Mar 16;14(636):eabg8402. doi: 10.1126/scitranslmed.abg8402. Epub 2022 Mar 16. Sci Transl Med. 2022. PMID: 35294258 Free PMC article.
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.
Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. Muthuswamy R, et al. Among authors: battaglia s. J Immunother Cancer. 2021 Oct;9(10):e003329. doi: 10.1136/jitc-2021-003329. J Immunother Cancer. 2021. PMID: 34607898 Free PMC article.
42 results